Kyverna Therapeutics

Kyverna Therapeutics (NASDAQ: KYTX) will host a live webcast and conference call on Dec 15, 2025 at 8:00 a.m. ET to present topline data from its registrational Phase 2 KYSA‑8 trial of the CD19 CAR‑T therapy KYV‑101 in stiff‑person syndrome. Registration is required for dial‑in details; the webcast and slides will be available on the investor‑relations site afterward. Ahead of the call, KYTX shares closed at $8.78, rose 5.0% on elevated volume, and the company cites a $150 M non‑dilutive loan and $171 M cash runway supporting a planned BLA filing in early 2026.

Kyverna Therapeutics will present interim Phase 2 KYSA-6 trial results for KYV-101 in myasthenia gravis at the AANEM meeting in October 2025. Data from six patients with up to 9 months follow-up will be shared. KYV-101, a CD19 CAR T-cell therapy, aims for durable remission after a single dose. The study has been upgraded to a registrational Phase 2/3 trial, with Phase 3 initiation planned by year-end 2025. The presentation by Dr. Srikanth Muppidi will be on October 29th.